Clarithromycin

克拉霉素

Report date: 2026/03/17 20:00:15
NME

Base Information

Drug NameClarithromycin
Drug Alias NameKlaritromycinKlarithromycinClaritromicinaClarithromycineKlaritromicinas +[26] 
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > Macrolides antibiotics
Mechanisms of Action50S ribosomal subunit inhibitors
Targets50S ribosomal subunit
Therapy Area/IndicationsAcute BronchitisCoronavirus Disease 2019 (COVID-19)Uncomplicated skin and skin structure infections +[46] 
Global Approved IndicationsAcute BronchitisUncomplicated skin and skin structure infectionsHelicobacter pylori infection +[19] 
Approved Indications in ChinaAcute BronchitisLower Respiratory Tract InfectionsSinusitis +[6] 
Original Approved Country/TerritoryJapan
Original Approved Date1991/03/29
Country/TerritoryBelgiumCanadaUnited States +[14] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesTaisho Pharmaceutical Holdings Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHellenic Institute For The Study Of SepsisAll India Institute Of Medical Sciences, BhubaneswarNational Institute Of Neurological Disorders And Stroke +[8] 
Inactive CompaniesAbbott LaboratoriesUniversity Of KarachiSandoz +[15] 
Active IndicationsAcute BronchitisCommunity Acquired PneumoniaHelicobacter pylori infection +[23] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Uncomplicated skin and skin structure infectionsCachexia +[23] 

Other Information

ATC CodeJ01FA09
Related LinksWikipediaDrugBankKEGG